Citicoline in Non–arteritic Anterior Ischemic Optic Neuropathy: Pattern Electroretinography review
Article Sidebar
-
citicoline, non–arteritic anterior ischemic optic neuropathy, pattern electroretinography, retinal ganglion cell thickness, visual field
Abstract
This study aims to assess 1000 mg citicoline each day given for 60 days on chronic phase NAION (non–arteritic anterior ischemic optic neuropathy) patients. Double masked randomized clinical trial divided the patients into 2 groups: citicoline group (C–NAION) and placebo group (P–NAION). Analysis was done in 17 patients in each group. There were increament of ? amplitude P50 30 days in C–NAION group (0,775±2,6 µV) and ? amplitude N95 60 days in C–NAION group (–0,356±2,992 µV) but statistically insignificant compared to P–NAION. Age has a good correlation with ? amplitude P50 (r = –0.517; p = 0.002). Subjects with 1 risk factor experienced a higher ? amplitude of P50 than the subjects with more than 1 risk factor (1.856 ± 2.121 ?V vs –0.26 ± 2.45; p = 0.025). Citicoline did not show any changes in Retinal Ganglion Cell Thickness. There were improvement of ? mean deviation 60 days in C–NAION group (3,13±6,467 dB), but statistically insignificant compared to P–NAION. Citicoline tends to increase the ? amplitude of P50, N95 and mean deviation in chronic phase NAION. Age and the number of risk factors affects the increase of ? amplitude P50.
Full text article
References
Miller NR, Arnold AC. Current concepts in the diagnosis, pathogenesis and management of nonarteritic anterior ischaemic optic neuropathy. Eye (Lond) 2015;29(1):65–79.
Shauna B, Weijie VL, et al. Nonarteritic ischemic optic neuropathy: cause, effect and management. Eye Brain. 2017; 9:23-8.
Sharma S, Ang M, et al. Optical coherence tomography angiography in acute non-arteritic anterior ischaemic optic neuropathy. Br J Ophthalmol. 2017;101(8):1045–51.
Patel HR, Margo CE. Pathology of Ischemic Optic Neuropathy. Arch Pathol Lab Med. 2017; 141(1): 162–166. pmid:28029908
Han S, Jung JJ, et al. Differences between non-arteritic anterior ischemic optic neuropathy and open angle glaucoma with altitudinal visual field defect. Korean J Ophthalmol. 2016;29(6):418–423.
Ischaemic optic neuropathy decompression trial (IONDT). Characteristic of patients with nonarteritic anterior ischemic optic neuropathy eligible for the ischemic optic neuropathy decompression trial. Arch Ophthalmol. 1996;114:1366–74.
Hayreh SS, Zimmerman MB. Non–arteritic anterior ischemic optic neuropathy: role of systemic corticosteroid therapy. Ger J Ophthalmol. 2008;246:1029–46.
Oshitari T, Fujimoto N, et al. Citicoline has a protective effect on damaged retinal ganglion cells in mouse culture retina. Neurol Report. 2002; 13: 2109–11.
Parisi V, Coppola G, et al. Cytidine 5–diphosphocoline (citicoline): a pilot study in patients with non–arteritic ischemic optic neuropathy. Eur J Neurol. 2008, 15: 465–74.
SJ Heon, HYL Park, et al. Relationship between pattern electroretinogram and optic disc morphology in glaucoma. PLOS ONE.2019. https://doi.org/10.1371/journal.pone.0220992
Bach M, Brigell MG, et al. ISCEV standard for clinical pattern electroretinography (PERG): 2017 update. Doc Ophthalmol 2013; 126: 1–7.
Porciatti V. Electrophysiological assessment of retinal ganglion cell function. Exp Eye Res. 2017; 141:164–170.
Chitu L, T Ruxandra, et al. Citicoline- a neuroprotector with proven effects on glaucomatous disease. Rom J Ophthalmol. 2017 Jul-Sep; 61(3): 152–158
Babb SM, Appelmans KE, et al. Differential effect of CDP–choline on brain cytosolic choline levels in younger and older subjects as measured by proton magnetic resonance spectroscopy. Psychopharmacology (Berl). 1996;127(2):88–94.
Rusenberg BM, Pavlidids M, et al. Pathological changes in human retinal ganglion cells associated with diabetic and hypertensive retinopathy. Graefe’s Archive for Clinical and Experimental Ophtalmology. 2006. 245(7) : 1009–18.
Idiculla J, Nithyanandam S, et al. Serum lipids and diabetic retinopathy: A cross–sectional study. Indian J Endocrinol Metabl.2012.16(2):492–4
Secades JJ. Citicoline: pharmacological and clinical review, 2016 update. Nat Rev Neurol. 2017; 52 (Suppl 2): 51–62
Authors
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.